GW Henssler & Associates’s Aerie Pharmaceuticals AERI Stock Holding History

GW Henssler & Associates’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,425	Closed	-$334K	–	136
2018 Q3	$334K	Buy	+5,425	New	+$349K	0.03%	114

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GW Henssler & Associates's AERI Position: Q4 2018 in Review

GW Henssler & Associates sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 5,425 shares — an estimated $334K sold.

GW Henssler & Associates first reported a position in AERI in Q3 2018 and held it in 1 quarter. The position peaked at $334K in Q3 2018. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

GW Henssler & Associates reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
GW Henssler & Associates sold 5,425 Aerie Pharmaceuticals shares in Q4 2018, an estimated $334K.
GW Henssler & Associates first reported a position in Aerie Pharmaceuticals in Q3 2018 and held it in 1 quarter.
GW Henssler & Associates's Aerie Pharmaceuticals position peaked at $334K in Q3 2018.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on GW Henssler & Associates's 13F filing for Q4 2018, filed 22 Jan 2019.